Monoclonal antibodies to clostridia glutamate dehydrogenase
ViroStat has announces the release of new monoclonal antibody pairs to clostridia glutamate dehydrogenase (GDH), validated by enzyme-linked immunosorbent assay (ELISA). These antibodies represent a new set of tools for rapid detection.
Clostridium difficile-associated diarrhoea (CDAD) is the leading cause of nosocomial diarrhoea. The spread of this bacterium is difficult to control due to its resistant spores that survive on many surfaces. Thus, rapid detection is crucial to its control. Most rapid tests target the toxins (A & B) produced during the infection.
Another diagnostic target is GDH, an enzyme produced and released during bacterial growth. Studies have shown that adding GDH detection together with toxin detection by enzyme-linked immunoassay (EIA) or polymerase chain reaction (PCR) significantly improves assay specificity.
ViroStat is a primary manufacturer, supplying infectious disease reagents to researchers and rapid test manufacturers. Data sheets for these antibodies can be downloaded from the company website, as can a copy of the new ViroStat catalogue.
Other News
Featured Supplier
DiaSorin is an Italian multinational Group and a global leader in the market for in vitro diagnostics. DiaSorin is listed on the MTA (automated stock market) in the FTSE Italia Mid Cap Index, organized and managed by Borsa Italiana S.p.A
For over 40 years the Group has been developing, producing and commercializing diagnostic tests for a wide...
Upcoming Events
Every Minute Counts: a SHOT, BBTS and NBTC joint webinar
Online
3 December 2021
IBMS Biomedical Science Congress 2022
International Convention Centre, Birmingham
14-17 March 2022
Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.
Download the FREE Pathology In Practice app from your device's App store
